www.fdanews.com/articles/74164-glaxo-to-co-develop-human-genome-drug
GLAXO TO CO-DEVELOP HUMAN GENOME DRUG
July 11, 2005
GlaxoSmithKline has decided to exercise its option to jointly develop and commercialize an experimental arthritis treatment with Human Genome Sciences. Human Genome is developing LymphoStat-B as a potential treatment for rheumatoid arthritis and systemic lupus erythematosus, already establishing the drug's safety and efficacy during initial clinical trials. LymphoStat-B is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator.